AstraZeneca to sell commercial rights to Atacand in more than 70 countries to Cheplapharm
The FINANCIAL — AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of hypertension. Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit,
Latest comments